HUT73392A - Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation/thereof - Google Patents
Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation/thereof Download PDFInfo
- Publication number
- HUT73392A HUT73392A HU9503028A HU9503028A HUT73392A HU T73392 A HUT73392 A HU T73392A HU 9503028 A HU9503028 A HU 9503028A HU 9503028 A HU9503028 A HU 9503028A HU T73392 A HUT73392 A HU T73392A
- Authority
- HU
- Hungary
- Prior art keywords
- immuno
- nanoparticles
- antibodies
- nanoparticles according
- antibody
- Prior art date
Links
- 239000002105 nanoparticle Substances 0.000 claims description 74
- 229920000642 polymer Polymers 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- XJDDLMJULQGRLU-UHFFFAOYSA-N 1,3-dioxane-4,6-dione Chemical compound O=C1CC(=O)OCO1 XJDDLMJULQGRLU-UHFFFAOYSA-N 0.000 claims description 5
- 239000013060 biological fluid Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 239000003153 chemical reaction reagent Substances 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 108010041397 CD4 Antigens Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000004793 Polystyrene Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229940088623 biologically active substance Drugs 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- -1 methylidene malonate compound Chemical class 0.000 claims description 2
- 229920002223 polystyrene Polymers 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 13
- 238000011534 incubation Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- IJVRPNIWWODHHA-UHFFFAOYSA-N 2-cyanoprop-2-enoic acid Chemical compound OC(=O)C(=C)C#N IJVRPNIWWODHHA-UHFFFAOYSA-N 0.000 description 1
- HFQQYIUTYJVYFZ-UHFFFAOYSA-N 4-methylpentyl 2-cyanoprop-2-enoate Chemical compound CC(C)CCCOC(=O)C(=C)C#N HFQQYIUTYJVYFZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- XDZLHTBOHLGGCJ-UHFFFAOYSA-N hexyl 2-cyanoprop-2-enoate Chemical compound CCCCCCOC(=O)C(=C)C#N XDZLHTBOHLGGCJ-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000002976 reverse transcriptase assay Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9304750A FR2704227B1 (fr) | 1993-04-22 | 1993-04-22 | Immunonanoparticules porteuses d'anticorps monoclonaux anti-cd4 et leur utilisation pour la prophylaxie et/ou le traitemeent de pathologies dues a une infection par le virus hiv. |
| US10170093A | 1993-08-04 | 1993-08-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU9503028D0 HU9503028D0 (en) | 1995-12-28 |
| HUT73392A true HUT73392A (en) | 1996-07-29 |
Family
ID=26230266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9503028A HUT73392A (en) | 1993-04-22 | 1994-04-22 | Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation/thereof |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0695312A1 (ja) |
| JP (1) | JPH08512287A (ja) |
| CN (1) | CN1121725A (ja) |
| AU (1) | AU6681494A (ja) |
| CA (1) | CA2160983A1 (ja) |
| CZ (1) | CZ276295A3 (ja) |
| FI (1) | FI954827A0 (ja) |
| HU (1) | HUT73392A (ja) |
| SK (1) | SK130395A3 (ja) |
| WO (1) | WO1994024168A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722411B1 (fr) * | 1994-07-18 | 1996-10-04 | Union Pharma Scient Appl | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv |
| JP4611561B2 (ja) * | 2000-04-12 | 2011-01-12 | Ｄｉｃ株式会社 | 新規なビニル系樹脂およびその製造方法 |
| GB2381792B (en) * | 2000-04-12 | 2004-08-04 | Dainippon Ink & Chemicals | Antifouling coating composituion |
| JP3961312B2 (ja) | 2002-02-26 | 2007-08-22 | 株式会社デンソー | 内燃機関の制御装置 |
| WO2012113348A1 (zh) * | 2011-02-25 | 2012-08-30 | 厦门大学 | 抗cd4蛋白的单克隆抗体及其活性片段及用途 |
| CN110903394B (zh) * | 2019-12-27 | 2021-09-07 | 源道隆（苏州）医学科技有限公司 | 可结合cd4的多肽及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0329184A3 (en) * | 1988-02-19 | 1990-05-23 | Neorx Corporation | Antimers and antimeric conjugation |
-
1994
- 1994-04-22 SK SK1303-95A patent/SK130395A3/sk unknown
- 1994-04-22 CA CA002160983A patent/CA2160983A1/en not_active Abandoned
- 1994-04-22 EP EP94914433A patent/EP0695312A1/fr not_active Ceased
- 1994-04-22 CZ CZ952762A patent/CZ276295A3/cs unknown
- 1994-04-22 WO PCT/FR1994/000459 patent/WO1994024168A1/fr not_active Application Discontinuation
- 1994-04-22 JP JP6522857A patent/JPH08512287A/ja active Pending
- 1994-04-22 CN CN94191869A patent/CN1121725A/zh active Pending
- 1994-04-22 AU AU66814/94A patent/AU6681494A/en not_active Abandoned
- 1994-04-22 HU HU9503028A patent/HUT73392A/hu unknown
-
1995
- 1995-10-11 FI FI954827A patent/FI954827A0/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI954827A (fi) | 1995-10-11 |
| WO1994024168A1 (fr) | 1994-10-27 |
| CN1121725A (zh) | 1996-05-01 |
| CZ276295A3 (en) | 1996-06-12 |
| CA2160983A1 (en) | 1994-10-27 |
| EP0695312A1 (fr) | 1996-02-07 |
| JPH08512287A (ja) | 1996-12-24 |
| HU9503028D0 (en) | 1995-12-28 |
| FI954827A0 (fi) | 1995-10-11 |
| SK130395A3 (en) | 1996-06-05 |
| AU6681494A (en) | 1994-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Arneborn et al. | T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella | |
| US8158575B2 (en) | Agent for the prevention and treatment of sexually transmitted diseases-I | |
| JP2001512565A (ja) | 疎水性表面への細胞及び生体分子の接着を調節するための組成物及び方法 | |
| Scoazec et al. | Both macrophages and endothelial cells of the human hepatic sinusoid express the CD4 molecule, a receptor for the human immunodeficiency virus | |
| Hamzaoui et al. | Natural killer cells in Behçet's disease. | |
| JPH04505010A (ja) | 免疫調節障害の処置のための薬剤生成物 | |
| Castilletti et al. | HIV type 1 grown on interferon γ-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells | |
| AU2002245932A1 (en) | Agent for the prevention and treatment of sexually transmitted diseases-I | |
| HUT73392A (en) | Immunoparticles bearing monoclonal anti-cd4 antibodies and utilisation/thereof | |
| Sadat-Sowti et al. | Alveolar CD8+ CD57+ lymphocytes in human immunodeficiency virus infection produce an inhibitor of cytotoxic functions. | |
| Pontani et al. | Inhibition of HIV replication by liposomal encapsulated amphotericin B | |
| JPH05504882A (ja) | ヒト末梢血液単核細胞のアミノ酸アミド処理によるｌａｋ細胞活性化増強 | |
| Toth et al. | Differential replication of human immunodeficiency virus type 1 in CD8-and CD8+ subsets of natural killer cells: relationship to cytokine production pattern | |
| FR2722411A1 (fr) | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv | |
| WO2005083427A1 (fr) | Procede d'essai de specification de l'activation de lymphocytes | |
| York et al. | Cyclosporin abrogates virus-specific T-cell control of EBV-induced B-cell lymphoproliferation | |
| WO2002079298A1 (en) | Agents for the prevention and treatment of sexually transmitted diseases -ii | |
| EP2537880A2 (en) | Carbosilane dendrimers and the use thereof as antiviral agents | |
| Abbate et al. | Host cell antigenic profile acquired by HIV-1 is a marker of its cellular origin | |
| FR2704227A1 (fr) | Immunonanoparticules porteuses d'anticorps monoclonaux anti-CD4 et leur utilisation pour la prophylaxie et/ou le traitemeent de pathologies dues à une infection par le virus HIV. | |
| Burmester et al. | Dissociation of helper/inducer T-cell functions: immunodeficiency associated with mycobacterial histiocytosis | |
| Wang et al. | Use of flow cytometry in the in vitro and in vivo analysis of tolerance/anergy induction by immunocamouflage | |
| Kabeya et al. | Bovine leukaemia virus envelope peptides cause immunomodulation in BALB/c mice | |
| Favero et al. | Inhibition of HIV Infection by Lectin Binding to CD4 | |
| Stanek et al. | Natural killer cell function in ankylosing spondylitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFD9 | Temporary protection cancelled due to non-payment of fee |